Biomarker improvement and development in non-endoscopic samples

Submission date	Recruitment status No longer recruiting	Prospectively registered	
20/12/2022		[X] Protocol	
Registration date	Overall study status Ongoing	[] Statistical analysis plan	
31/01/2023		[_] Results	
Last Edited 31/01/2023	Condition category Digestive System	Individual participant data	
		[_] Record updated in last year	

Plain English summary of protocol

Background and study aims

In the past two years, Cyted Ltd (UK) has provided more than 10,000 non-endoscopic based tests for Barrett's oesophagus and Oesophageal adenocarcinoma. These tests have enabled NHS Trusts to address the endoscopic backlog created during COVID. Cyted's current test relies on a pathologist reading a standard haematoxylin and eosin (H&E) stained slide alongside a slide-based antibody stain (TFF3) to diagnose Barrett's, and a separate slide-based antibody stain (P53) to identify patients at who are at a high risk of cancer. We aim to improve these tests, ensuring that patients continue to be provided with the best information available regarding their personal disease risk. This includes expanding our ability to test for oesophageal squamous cell carcinoma (OSCC) and other oesophageal diseases such as eosinophilic oesophagitis (EoE).

Who can participate?

Samples collected from patients with Barrett's oesophagus and Oesophageal adenocarcinoma during a routine diagnostic procedure

What does the study involve?

This study intends to:

1. Improve the accuracy of our existing artificial intelligence platform with the inclusion of additional slide images from our diagnostic archive

2. Develop additional biomarkers to supplement the existing slide-based stains (i.e. TFF3, P53) for diagnosis and risk stratification in Barrett's screening and surveillance samples - Identify diagnostic biomarkers for OSCC and EoE

Improvements to these diagnostic tests will also enable improvements in our pathology reporting to NHS Trusts through increased accuracy for cancer risk, and screening for other diseases (i.e. EoE) that are currently only available through endoscopic sampling.

What are the possible benefits and risks of participating? Not provided at time of registration.

Where is the study run from? Cyted Ltd (UK) When is the study starting and how long is it expected to run for? November 2022 to December 2025

Who is funding the study? Cyted Ltd (UK)

Who is the main contact? Dr Sarah Killcoyne (Principal investigator), sarah.killcoyne@cyted.ai (UK) Ms Basirat Afinowi, basirat.afinowi@cyted.ai (UK)

Contact information

Type(s) Principal Investigator

Contact name Dr Sarah Killcoyne

ORCID ID http://orcid.org/0000-0003-3686-6167

Contact details 22 Station Road Cambridge United Kingdom CB1 2JD +44 (0)1480 453 437 sarah.killcoyne@cyted.ai

Type(s)

Public

Contact name Ms Basirat Afinowi

Contact details

22 Station Road Cambridge United Kingdom CB1 2JD +44 (0)1480 453 437 basirat.afinowi@cyted.ai

Additional identifiers

EudraCT/CTIS number Nil known

IRAS number 322308 **ClinicalTrials.gov number** Nil known

Secondary identifying numbers IRAS 322308

Study information

Scientific Title

Biomarker improvement and development in non-endoscopic samples within the Cyted diagnostic pathway

Study objectives

This study's primary objective is to improve our available biomarker tests to ensure continued high-quality diagnostic information is provided to patients. This will be achieved by identifying additional biomarkers that can be used in addition to, or as an alternative to the current TFF3 /P53/atypia slide-based stains.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approved 05/12/2022, South Central - Berkshire B Research Ethics Committee (The Old Chapel, Royal Standard Place, Nottingham, NG1 6FS, UK; +442071048276; berkshireb.rec@hra.nhs.uk), ref: 22/SC/0470

Study design Single-centre retrospective cohort study

Primary study design Observational

Secondary study design Cohort study

Study setting(s) Other

Study type(s) Diagnostic

Participant information sheet No participant information sheet available

Health condition(s) or problem(s) studied

Diagnosis of oesophageal conditions in patients with reflux including Barrett's oesophagus, Oesophageal cancer, and Eosinophilic oesophagitis.

Interventions

This study is a single-centre retrospective cohort study using diagnostic samples collected during a routine diagnostic procedure and reported a minimum of 3 months prior to inclusion.

A targeted set of molecular tests will be run to assess sufficiency for the existence of specific cell types relating to disease, sensitivity/specificity analysis in comparison to existing methods and assess what the normal/healthy range is in patients without cancer. Image-based machine learning methods will include analysis of cellular mixtures and ratios of cell types in different cohorts and an accuracy assessment for our internal quality control procedures.

Intervention Type

Other

Primary outcome measure

1. Sensitivity/specificity for any new biomarker for the given endpoint (1) diagnosis of Barrett's by endoscopy OR (2) risk of cancer) at the end of the study

2. Accuracy as measured against the pathologist's diagnosis for Barrett's diagnosis at the end of the study

Secondary outcome measures

1. General improvements to our internal laboratory processes for sample testing and reporting to pathologists. Improvements are measured against the current internal standard for sample processing. Each improvement will be evaluated against an appropriate internal sample set, sample size calculations will be performed based on the specific process we address. The final timepoint for all improvement studies will be the end of the study.

2. Identification of biomarkers for other oesophageal conditions including EoE or OSCC measured using a combination of IHC biomarkers, the gold standard for any new biomarker is our pathologist's diagnosis and non-inferiority with our current IHC biomarker tests. Timepoint is at the end of the study.

Overall study start date

01/11/2022

Completion date

31/12/2025

Eligibility

Key inclusion criteria

1. Patient aged 18 and over

- 2. Male or female
- 3. Final pathology report submitted a minimum of 3 months prior to search

Participant type(s) All

Age group Adult

Lower age limit 18 Years **Sex** Both

Target number of participants 10000

Key exclusion criteria1. Samples submitted less than 3 months prior search2. Samples that have not yet resulted in a pathology report

Date of first enrolment 01/01/2023

Date of final enrolment 01/12/2023

Locations

Countries of recruitment England

United Kingdom

Study participating centre Cyted Ltd 22 Station Road Cambridge United Kingdom CB1 2JD

Sponsor information

Organisation

Cyted Ltd

Sponsor details

22 Station Road Cambridge England United Kingdom CB1 2JD +44 (0)1480 453 437 hello@cyted.ai

Sponsor type

Industry

Website https://cyted.ai/

Funder(s)

Funder type Industry

Funder Name Cyted Ltd

Results and Publications

Publication and dissemination plan

1. Planned publication in a high-impact and peer-reviewed journal

2. Submissions to regulatory authorities where appropriate

Intention to publish date

01/12/2026

Individual participant data (IPD) sharing plan

Summary datasets generated during and/or analysed during the current study will be published as a supplement to the results publication. Individual results will not be made available to ensure anonymisation is preserved.

IPD sharing plan summary

Published as a supplement to the results publication

Study outputs								
Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?			
Protocol file	version 1.0	11/11/2022	22/12/2022	No	No			
HRA research summary			28/06/2023	No	No			